Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1980 1
1983 1
1985 1
1989 1
1990 1
1992 1
1993 2
1995 2
1996 1
1997 2
1998 1
2000 2
2001 4
2002 3
2003 1
2004 4
2005 3
2006 3
2007 5
2008 3
2009 4
2010 2
2011 1
2012 4
2013 10
2014 12
2015 6
2016 8
2017 7
2018 3
2019 4
2020 6
2021 6
2022 11
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Indolent plasma cell myeloma"
Page 1
Follicular lymphoma: The long and winding road leading to your cure?
Gordon MJ, Smith MR, Nastoupil LJ. Gordon MJ, et al. Blood Rev. 2023 Jan;57:100992. doi: 10.1016/j.blre.2022.100992. Epub 2022 Jul 23. Blood Rev. 2023. PMID: 35908982 Review.
Follicular lymphoma, the most common indolent lymphoma, though highly responsive to therapy is coupled with multiple relapses for the majority of patients. ...Mutations are also commonly identified in other proliferation/survival pathways such as B-cell recep …
Follicular lymphoma, the most common indolent lymphoma, though highly responsive to therapy is coupled with multiple relapses …
Multiple myeloma.
Bladé J, Cibeira MT, Fernández de Larrea C, Rosiñol L. Bladé J, et al. Ann Oncol. 2010 Oct;21 Suppl 7:vii313-9. doi: 10.1093/annonc/mdq363. Ann Oncol. 2010. PMID: 20943635 Free article. Review.
Multiple myeloma (MM) constitutes 1% of malignant diseases and 15% of haematological malignancies. ...A sequential approach is preferred over combination of multiple agents. Supportive measures include the use of bisphosphonates and erythropoietin according t …
Multiple myeloma (MM) constitutes 1% of malignant diseases and 15% of haematological malignancies. ...A sequential approach is …
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402. Am J Hematol. 2016. PMID: 27291302 Free PMC article. Review.
Multiple myeloma accounts for approximately 10% of hematologic malignancies.The diagnosis requires 10% clonal bone marrow plasma cells or a biopsy proven plasmacytoma plus evidence of one or more multiple myeloma defining events (MDE): CRAB (hyp …
Multiple myeloma accounts for approximately 10% of hematologic malignancies.The diagnosis requires 10% clonal bone marrow p …
Plasma cell neoplasia after kidney transplantation: French cohort series and review of the literature.
Kormann R, François H, Moles T, Dantal J, Kamar N, Moreau K, Bachelet T, Heng AE, Garstka A, Colosio C, Ducloux D, Sayegh J, Savenkoff B, Viglietti D, Sberro R, Rondeau E, Peltier J. Kormann R, et al. PLoS One. 2017 Jun 21;12(6):e0179406. doi: 10.1371/journal.pone.0179406. eCollection 2017. PLoS One. 2017. PMID: 28636627 Free PMC article. Review.
We included twenty-two cases of post-transplant PCN occurring between 1991 and 2013. These included 12 symptomatic multiple myeloma, eight indolent myeloma and two plasmacytomas. The median age at diagnosis was 56.5 years and the median onset after tra …
We included twenty-two cases of post-transplant PCN occurring between 1991 and 2013. These included 12 symptomatic multiple myelom …
Extramedullary disease in plasma cell myeloma: the iceberg phenomenon.
Wirk B, Wingard JR, Moreb JS. Wirk B, et al. Bone Marrow Transplant. 2013 Jan;48(1):10-8. doi: 10.1038/bmt.2012.26. Epub 2012 Mar 12. Bone Marrow Transplant. 2013. PMID: 22410751 Review.
Extramedullary (EM) plasmacytomas (EMPs) that are not progression of intramedullary (IM) plasma cell myeloma (PCM) are usually indolent. In contrast, EM spread of IM PCM is associated with a poor prognosis. ...For example, EM relapse in PCM with and wi …
Extramedullary (EM) plasmacytomas (EMPs) that are not progression of intramedullary (IM) plasma cell myeloma (PCM) are …
Management of the elderly patient with AL amyloidosis.
Nuvolone M, Milani P, Palladini G, Merlini G. Nuvolone M, et al. Eur J Intern Med. 2018 Dec;58:48-56. doi: 10.1016/j.ejim.2018.05.004. Epub 2018 May 23. Eur J Intern Med. 2018. PMID: 29801808 Review.
Systemic immunoglobulin light chain (AL) amyloidosis is an aging-associated protein misfolding and deposition disease. This condition is caused by a small and otherwise indolent plasma cell (or B cell) clone secreting an unstable circulating light chai …
Systemic immunoglobulin light chain (AL) amyloidosis is an aging-associated protein misfolding and deposition disease. This condition is cau …
Advances in the pathogenesis and diagnosis of multiple myeloma.
Chesi M, Bergsagel PL. Chesi M, et al. Int J Lab Hematol. 2015 May;37 Suppl 1:108-14. doi: 10.1111/ijlh.12360. Int J Lab Hematol. 2015. PMID: 25976968 Review.
Multiple myeloma (MM) is a tumor of indolent, bone marrow (BM) localized, isotype-switched plasma cells. ...Genetically it can be divided into tumors with different recurrent immunoglobulin heavy chain gene translocations (4p16, 11q13, 6p21, 16q23, 20q …
Multiple myeloma (MM) is a tumor of indolent, bone marrow (BM) localized, isotype-switched plasma cells. ...Gene …
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management.
Rajkumar SV. Rajkumar SV. Am J Hematol. 2011 Jan;86(1):57-65. doi: 10.1002/ajh.21913. Am J Hematol. 2011. PMID: 21181954 Free article. Review.
DISEASE OVERVIEW: Multiple myeloma is malignant plasma-cell disorder that accounts for 10% of all hematologic malignancies. DIAGNOSIS: The diagnosis requires (1) 10% or more clonal plasma cells on bone marrow examination or a biopsy-proven plasm …
DISEASE OVERVIEW: Multiple myeloma is malignant plasma-cell disorder that accounts for 10% of all hematologic ma …
Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management.
Vincent Rajkumar S. Vincent Rajkumar S. Am J Hematol. 2014 Oct;89(10):999-1009. doi: 10.1002/ajh.23810. Am J Hematol. 2014. PMID: 25223428 Free article. Review.
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. ...If end-organ damage is not present, the presence of 60% or more clonal plasma cells in the marrow is also considered as myeloma. RISK STRATIFICATION: In t …
DISEASE OVERVIEW: Multiple myeloma accounts for approximately 10% of hematologic malignancies. ...If end-organ damage is not p …
Risk Stratification and Treatment in Smoldering Multiple Myeloma.
Lussier T, Schoebe N, Mai S. Lussier T, et al. Cells. 2021 Dec 31;11(1):130. doi: 10.3390/cells11010130. Cells. 2021. PMID: 35011692 Free PMC article. Review.
Smoldering multiple myeloma is a heterogeneous asymptomatic precursor to multiple myeloma. ...Genetic approaches include gene expression profiling, DNA/RNA sequencing, and cytogenetics. It is important to accurately distinguish patients with indolen …
Smoldering multiple myeloma is a heterogeneous asymptomatic precursor to multiple myeloma. ...Genetic approaches …
118 results